Abstract
A hormonal therapy has been the first choice for advanced prostate cancer. Recently, LH-RH analogue whose clinical efficacy was considered equivalent to a castration and estrogens took a place of them and occupies a prominent position in a prostate cancer therapy. An LH-RH analogue and its controlled-release formulation led to a number of clinical trials not only as a monotherapy but also as an adjuvant of surgery and radiation therapy in various clinical situations. The development of controlled-release formulation of LH-RH analogue and a profile of its clinical trials were reviewed.
